Focusing on Fragile X
Pharmacology Doctoral Student Martinez Receives FASEB-MARC Travel Award to Present Fragile X Syndrome Research at EB 2016
Pharmacology doctoral candidate Luis Martinez, working in the lab of UHCOP Associate Professor Maria V. Tejada-Simon, Ph.D., M.Ed. ('07), will present their latest findings on their research into the autism-linked genetic syndrome known as Fragile X Syndrome (FXS) at the 2016 Experimental Biology Meeting April 2-6 in San Diego.
Fragile X Syndrome (FXS) is an inherited cause of intellectual disability, especially among boys. It results in a spectrum of intellectual disabilities ranging from mild to severe as well as physical characteristics such as an elongated face, large or protruding ears, and large testes (macroorchidism), and behavioral characteristics such as stereotypic movements (e.g. hand-flapping), and social anxiety.
Cognitive impairment in neurodevelopmental disorders like FXS is thought to be due to abnormal neuroplasticity (the developmental changes in the brain), which alters synaptic connections. Previous research has suggested that a specific protein in the hippocampus, which is considered the "seat" of learning and memory, does not migrate to the appropriate spot in mouse models of FXS vs. wild-type mice.
Work by Tejada-Simon's lab as well as other researchers have found that Rac1 (a protein of the Rho family) plays an important role in synapse formation, with an abnormally high number of synapses occurring in FXS mouse models following the newborn-to-juvenile developmental stages.
"During their developmental aging and growth into juvenile stage, the FXS mouse model – in which Rac1 expression is up-regulated – fail to undergo 'pruning' of the surplus of synapse neural connections," said Martinez, who earned a double-major B.S. in Biology and Biochemistry from UH in 2005. "Yet, we found that by pharmacologically inhibiting Rac1 to prevent its activation and membrane translocation, we were able to rescue cognitive function to improve their learning and memory skills."
Following peer review of Martinez's poster abstract submission, entitled "Correcting memory deficits in Fragile X syndrome by targeting Rac1/PAK1 signaling," he was invited to also present their findings in an oral presentation at the Julius Axelrod Symposium: New Vistas on Drug and Gene Therapies of Cognitive Deficits in Down Syndrome, Autism, Leucodystrophies and Alzheimer's Disease. The symposium oral presentation and the poster presentation sessions are both part of the American Society for Pharmacology and Experimental Therapeutics' annual meeting, which is held in conjunction with EB.
To support his attendance and research presentations at the meeting, Martinez received a 2016 Federation of American Societies for Experimental Biology (FASEB) Maximizing Access to Research Careers (MARC) Program Travel Award and complementary meeting registration.
Martinez is one of 49 students, post-doctoral fellows and scientists to receive a travel award to EB 2016 through the FASEB MARC Program, which is funded by a grant from the National Institute of General Medical Sciences, National Institutes of Health. A primary goal of the MARC Program is to increase the number and competitiveness of underrepresented groups engaged in biomedical and behavioral research.
One of the largest gatherings of its kind, Experimental Biology is an annual meeting comprising more than 14,000 scientists, undergraduate and graduate students, postdoctoral fellows and exhibitors representing six sponsoring societies and multiple guest societies.
FASEB is composed of 30 societies with more than 125,000 members, making it the largest coalition of biomedical research associations in the U.S. The organization's mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to its member societies and collaborative advocacy.